A Multicenter, Open-label, Long-term Follow-up Safety and Efficacy Study of GLPG0634 Treatment in Subjects With Moderately to Severely Active Rheumatoid Arthritis

Trial Profile

A Multicenter, Open-label, Long-term Follow-up Safety and Efficacy Study of GLPG0634 Treatment in Subjects With Moderately to Severely Active Rheumatoid Arthritis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Apr 2018

At a glance

  • Drugs Filgotinib (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Acronyms DARWIN-3
  • Sponsors Galapagos NV; Gilead Sciences
  • Most Recent Events

    • 08 Nov 2017 Safety results summarized from DARWIN-1, DARWIN-2 and DARWIN-3 trials and efficacy results from DARWIN-3 trial presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
    • 05 Nov 2017 According to a Galapagos NV media release, additional long-term follow-up data from this trial will be presented at the American College of Rheumatology Annual Meeting 2017.
    • 20 Jun 2017 Interim results published in a Galapagos media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top